{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-078072","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.207731+00:00","generated_at":"2026-06-13T12:46:22.190642+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics approved to transfer stock listing from Nasdaq Global Select to Capital Market on July 6","bullets":["Received Nasdaq approval on July 3, 2023 to transfer listing from Global Select to Capital Market.","Transfer becomes effective at the opening of business on July 6, 2023.","Aprea's common stock (APRE) will continue trading on the Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-078072","json":"https://secwatch.observer/filing/0001104659-23-078072.json","markdown":"https://secwatch.observer/filing/0001104659-23-078072.md","text":"https://secwatch.observer/filing/0001104659-23-078072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923078072/0001104659-23-078072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923078072/tm2320610d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:46:22.190642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}